LIFE logo

aTyr Pharma (LIFE) Stock

Profile

Full Name:

aTyr Pharma, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 May 2015

Indexes:

Not included

Description:

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Aug 09, 2024

Recent annual earnings:

Mar 14, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

July 01, 2019

Analyst ratings

Recent major analysts updates

14 May '24 HC Wainwright & Co.
Buy
03 May '24 HC Wainwright& Co.
Buy
03 May '24 HC Wainwright & Co.
Buy
15 Mar '24 RBC Capital
Outperform
15 Mar '24 HC Wainwright & Co.
Buy
21 Feb '24 HC Wainwright & Co.
Buy
21 Sept '23 HC Wainwright & Co.
Buy
14 Sept '23 HC Wainwright & Co.
Buy
10 Aug '23 HC Wainwright & Co.
Buy
21 July '23 Piper Sandler
Overweight

Screeners with LIFE included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

Trilogy AI Announces Closing of LIFE Financing, Concurrent Private Placements
Trilogy AI Announces Closing of LIFE Financing, Concurrent Private Placements
Trilogy AI Announces Closing of LIFE Financing, Concurrent Private Placements
LIFE
newsfilecorp.com28 January 2025

Vancouver, British Columbia--(Newsfile Corp. - January 28, 2025) - Trilogy AI Corp. (CSE: TRAI) (OTCQB: TRAIF) (FSE: Y92)  (formerly, Ambari Brands Inc.) (the "Company") is pleased to announce, further to its press release dated December 16, 2024, that the Company has closed its non-brokered private placement financing (the "LIFE Offering") of 6,826,667 common shares (the "Common Shares") at C$0.07 per Common Share, for aggregate gross proceeds of approximately C$477,866.69. The Company has also closed its concurrent private placement financing (the "Private Placement") of 5,174,240 common shares (the "Private Placement Shares") at C$0.07 per Private Placement Share for aggregate gross proceeds of approximately C$362,196.82, and its private placement offering of Common Share purchase warrants (the "Warrant Offering" and together with the LIFE Offering and the Private Placement, the "Offerings"), issuing a total of 9,311,500 warrants (the "Warrants"), at a price of C$0.05 per Warrant for aggregate gross proceeds of C$465,575.

First commercial launch of biometric payment cards in Japan with LIFE CARD and IDEX Biometrics
First commercial launch of biometric payment cards in Japan with LIFE CARD and IDEX Biometrics
First commercial launch of biometric payment cards in Japan with LIFE CARD and IDEX Biometrics
LIFE
globenewswire.com27 January 2025

Oslo, Norway and Tokyo, Japan - 27 January 2025 – IDEX Biometrics enters a new market, together with LIFE CARD, Japan's most innovative credit card issuer. This marks the market introduction of biometric payment cards in Japan. LIFE CARD is targeting commercial deployment in the first half of 2025.

Armory Mining Corp. Closes LIFE Offering
Armory Mining Corp. Closes LIFE Offering
Armory Mining Corp. Closes LIFE Offering
LIFE
accessnewswire.com22 January 2025

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / January 22, 2025 / Armory Mining Corp. (CSE:ARMY)(OTC PINK:RMRYF)(FRA:2JS) (the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement LIFE offering (the "Offering") by issuing 5,016,111 common shares at a price of $0.135 per share for aggregate gross proceeds of $677,175. In connection with the Offering, the Company paid cash finder's fees of $65,017, issued 481,611 finder's warrants, and issued 370,500 finder's shares to eligible arm's length finders.

EdgeTI Closes C$4,999,490 Non-Brokered LIFE Private Placement Financing
EdgeTI Closes C$4,999,490 Non-Brokered LIFE Private Placement Financing
EdgeTI Closes C$4,999,490 Non-Brokered LIFE Private Placement Financing
LIFE
newsfilecorp.com20 January 2025

Arlington, Virginia--(Newsfile Corp. - January 20, 2025) - Edge Total Intelligence Inc. (TSXV: CTRL) (OTCQB: UNFYF) (FSE: Q5i) (the "Company", "edgeTI") is pleased to announce that further to its news release dated January 14, 2025, it has closed a non-brokered private placement offering pursuant to the listed issuer financing exemption (the "Offering") of 9,433,000 units of the Company ("Units") at a price per Unit of C$0.53 for aggregate gross proceeds of C$4,999,490. Each Unit consisted of one subordinate voting share in the capital of the Company (an "SVS") and one half of one SVS purchase warrant (each whole warrant, a "Warrant").

EdgeTI Announces LIFE Offering Private Placement
EdgeTI Announces LIFE Offering Private Placement
EdgeTI Announces LIFE Offering Private Placement
LIFE
newsfilecorp.com14 January 2025

Arlington, Virginia--(Newsfile Corp. - January 14, 2025) - Edge Total Intelligence Inc. (TSXV: CTRL) (OTCQB: UNFYF) FSE: Q5i) (the "Company", "edgeTI") is pleased to announce a non-brokered private placement financing (the "Offering") of up to 9,433,000 units of the Company ("Units") at a price per Unit of C$0.53 for aggregate gross proceeds of up to approximately $4,999,490. Each Unit shall consist of one subordinate voting share in the capital of the Company (an "SVS") and one half of one SVS purchase warrant (each whole warrant, a "Warrant").

Armory Mining Announces LIFE Offering and Appointment of Chairman
Armory Mining Announces LIFE Offering and Appointment of Chairman
Armory Mining Announces LIFE Offering and Appointment of Chairman
LIFE
accesswire.com23 December 2024

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / December 23, 2024 / Armory Mining Corp. (CSE:ARMY)(OTC PINK:RMRYF)(FRA:2JS) (the "Company") is pleased to announce a non-brokered private placement LIFE offering (the "Offering") for total gross proceeds of a minimum of $500,000 and up to a maximum of $680,000, consisting of a minimum of 3,703,703 common shares of the Company (each a "Common Share") and up to a maximum of 5,037,037 Common Shares at a price of $0.135 per Common Share (the "Offering Price"). In connection with the Offering, the Company may pay finder's fees consisting of: (i) cash finder's fees of up to 10.0% of the gross proceeds raised in respect of the Offering from subscribers introduced by such finders to the Company; (ii) finder shares in an amount equal to up to 10.0% of the number of Common Shares issued pursuant to the Offering; and (iii) finder warrants in an amount equal to up to 10.0% of the number of Common Shares issued pursuant to the Offering from subscribers introduced by such finders to the Company, exercisable at the Offering Price for a period of 48 months following the closing date of the Offering.

VERSES Closes Third Tranche of LIFE Offering
VERSES Closes Third Tranche of LIFE Offering
VERSES Closes Third Tranche of LIFE Offering
LIFE
globenewswire.com09 December 2024

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB:VRSSF) (“VERSES” or the “Company”) is pleased to announce that it closed the third tranche of its previously announced non-brokered private placement (the “LIFE Offering”) of units of the Company (the “LIFE Units”) for gross proceeds in this third tranche of $770,000 from a single investor. The first tranche of the LIFE Offering closed on November 8, 2024, for aggregate gross proceeds of $2,903,850 and the second tranche of the LIFE Offering closed on November 15, 2024, for aggregate gross proceeds of $512,800.

BluMetric Announces LIFE Offering & Concurrent Private Placement
BluMetric Announces LIFE Offering & Concurrent Private Placement
BluMetric Announces LIFE Offering & Concurrent Private Placement
LIFE
newsfilecorp.com26 November 2024

Ottawa, Ontario--(Newsfile Corp. - November 26, 2024) - BluMetric Environmental Inc. (TSXV: BLM) (OTCQX: BLMWF) ("BluMetric" or the "Company") is pleased to announce it has entered into an agreement with Clarus Securities Inc. ("Clarus" or the "Agent") pursuant to which Clarus has agreed to act as lead agent and sole bookrunner in connection with a best-efforts private placement, under the Listed Issuer Financing Exemption (as defined herein), to issue up to 4,375,000 common shares of the Company (the "Offered Shares") at $0.80 per Offered Share (the "Issue Price") for gross proceeds of up to $3,500,000 (the "Offering"). Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 - Prospectus Exemptions ("NI 45-106"), the Offering is being made to purchasers resident in all provinces of Canada, except Quebec, pursuant to the listed issuer financing exemption under Part 5A of NI 45-106 (the "Listed Issuer Financing Exemption").

GLOBE LIFE INC. DECLARES DIVIDEND
GLOBE LIFE INC. DECLARES DIVIDEND
GLOBE LIFE INC. DECLARES DIVIDEND
LIFE
prnewswire.com15 November 2024

MCKINNEY, Texas , Nov. 15, 2024 /PRNewswire/ -- Globe Life Inc. (NYSE: GL) announced that its Board of Directors has declared a quarterly dividend of $.2400 per share on all of the outstanding common stock of the Company held of record as of close of business of the Company's transfer agent on January 6, 2025. The dividend will be paid on January 31, 2025.

VERSES AI Inc. Announces Closing of First Tranche of LIFE Private Placement Offering
VERSES AI Inc. Announces Closing of First Tranche of LIFE Private Placement Offering
VERSES AI Inc. Announces Closing of First Tranche of LIFE Private Placement Offering
LIFE
globenewswire.com08 November 2024

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQX:VRSSF) (“VERSES” or the “Company”) is pleased to announce that it closed the first tranche of its previously announced non-brokered private placement of 5,807,700 units of the Company (the "LIFE Units") at a price of $0.50 per LIFE Unit (the “Offering Price”) for aggregate gross proceeds of $2,903,850 (the "LIFE Offering"). Each LIFE Unit will consist of one Class A Subordinate Voting share of the Company (a “Share”) and one-half of one Share purchase warrant (each whole warrant, a “Warrant”).

FAQ

  • What is the primary business of aTyr Pharma?
  • What is the ticker symbol for aTyr Pharma?
  • Does aTyr Pharma pay dividends?
  • What sector is aTyr Pharma in?
  • What industry is aTyr Pharma in?
  • What country is aTyr Pharma based in?
  • When did aTyr Pharma go public?
  • Is aTyr Pharma in the S&P 500?
  • Is aTyr Pharma in the NASDAQ 100?
  • Is aTyr Pharma in the Dow Jones?
  • When was aTyr Pharma's last earnings report?
  • When does aTyr Pharma report earnings?
  • Should I buy aTyr Pharma stock now?

What is the primary business of aTyr Pharma?

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

What is the ticker symbol for aTyr Pharma?

The ticker symbol for aTyr Pharma is NASDAQ:LIFE

Does aTyr Pharma pay dividends?

No, aTyr Pharma does not pay dividends

What sector is aTyr Pharma in?

aTyr Pharma is in the Healthcare sector

What industry is aTyr Pharma in?

aTyr Pharma is in the Biotechnology industry

What country is aTyr Pharma based in?

aTyr Pharma is headquartered in United States

When did aTyr Pharma go public?

aTyr Pharma's initial public offering (IPO) was on 07 May 2015

Is aTyr Pharma in the S&P 500?

No, aTyr Pharma is not included in the S&P 500 index

Is aTyr Pharma in the NASDAQ 100?

No, aTyr Pharma is not included in the NASDAQ 100 index

Is aTyr Pharma in the Dow Jones?

No, aTyr Pharma is not included in the Dow Jones index

When was aTyr Pharma's last earnings report?

aTyr Pharma's most recent earnings report was on 9 August 2024

When does aTyr Pharma report earnings?

The date for aTyr Pharma's next earnings report has not been announced yet

Should I buy aTyr Pharma stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions